<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi>-induced skin <z:mp ids='MP_0001651'>necrosis</z:mp> can occur as a clinical feature of <z:hpo ids='HP_0011874'>heparin-induced thrombocytopenia</z:hpo> syndrome </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0011874'>Heparin-induced thrombocytopenia</z:hpo> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndromes</z:e> have some clinical features in common, including <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and thrombotic events </plain></SENT>
<SENT sid="2" pm="."><plain>We describe a 46-year-old woman who developed extensive <z:mp ids='MP_0001651'>necrosis</z:mp> in the breast and other sites secondary to the use of enoxaparin after an elective hysterectomy </plain></SENT>
<SENT sid="3" pm="."><plain>During the postoperative period, diagnoses of <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> were made because of some clinical and laboratory features (<z:hpo ids='HP_0001250'>seizure</z:hpo>, <z:hpo ids='HP_0000123'>nephritis</z:hpo>, bicytopenia, positive nuclear antibody, and positive <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> with a previous thrombotic event) </plain></SENT>
<SENT sid="4" pm="."><plain>The patient's clinical course improved only after <z:chebi fb="0" ids="50858">corticosteroid</z:chebi> therapy and the suspension of enoxaparin </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0011874'>Heparin-induced thrombocytopenia</z:hpo> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndromes</z:e> can have platelet factor 4 as a common denominator in their pathogenesis because platelet factor 4 tetramers can bind Î²2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> molecules </plain></SENT>
<SENT sid="6" pm="."><plain>This case suggests that use of low-molecular-weight <z:chebi fb="0" ids="24505">heparins</z:chebi> could be more risky in patients with an underlying <z:e sem="disease" ids="C0021053" disease_type="Disease or Syndrome" abbrv="">immune disease</z:e> and/or could trigger immune reactions that must be analyzed in larger studies </plain></SENT>
</text></document>